You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Medical Care

Global Erythropoietic Protoporphyria (EPP) Treatment Market Research Report 2021, Competitive Analysis, Industry Growth Trends And Forecast 2027

Erythropoietic protoporphyria (EPP) is a rare inherited metabolic disorder caused by a deficiency of the enzyme ferrochelatase (FECH), which results from changes (mutations) in the FECH gene. Due to abnormally low levels of this enzyme, excessive amounts of protoporphyrin accumulate in the bone marrow, blood plasma, and red blood cells. Some patients with symptoms of EPP have a genetic change in a different gene called ALAS2. When a patient has a genetic change in this gene, the condition is referred to as X-linked protoporphyria (XLP).
Market Analysis and Insights: Global Erythropoietic Protoporphyria (EPP) Treatment Market
The global Erythropoietic Protoporphyria (EPP) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Erythropoietic Protoporphyria (EPP) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Erythropoietic Protoporphyria (EPP) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Erythropoietic Protoporphyria (EPP) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Erythropoietic Protoporphyria (EPP) Treatment market.
Erythropoietic Protoporphyria (EPP) Treatment Breakdown Data by Type
Hormonal Therapy
Adjunctive Therapies
Phototherapy
Erythropoietic Protoporphyria (EPP) Treatment Breakdown Data by Application
Hospital Pharmacies
Drug Stores
Retail Pharmacies
Online Pharmacies
Based on regional and country-level analysis, the Erythropoietic Protoporphyria (EPP) Treatment market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Erythropoietic Protoporphyria (EPP) Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2016-2021.
The following players are covered in this report:
Clinuvel Pharmaceuticals ALS
L'Oréal S.A.
Tishcon Corp.
In-Life Co.
Pfizer Inc.
Fenton Pharmaceuticals Ltd.
Teva Pharmaceuticals
Mylan N.V.
Johnson and Johnson
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Erythropoietic Protoporphyria (EPP) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Hormonal Therapy
1.2.3 Adjunctive Therapies
1.2.4 Phototherapy
1.3 Market by Application
1.3.1 Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.3.4 Retail Pharmacies
1.3.5 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Erythropoietic Protoporphyria (EPP) Treatment Market Perspective (2016-2027)
2.2 Erythropoietic Protoporphyria (EPP) Treatment Growth Trends by Regions
2.2.1 Erythropoietic Protoporphyria (EPP) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Erythropoietic Protoporphyria (EPP) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Erythropoietic Protoporphyria (EPP) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Erythropoietic Protoporphyria (EPP) Treatment Industry Dynamic
2.3.1 Erythropoietic Protoporphyria (EPP) Treatment Market Trends
2.3.2 Erythropoietic Protoporphyria (EPP) Treatment Market Drivers
2.3.3 Erythropoietic Protoporphyria (EPP) Treatment Market Challenges
2.3.4 Erythropoietic Protoporphyria (EPP) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Erythropoietic Protoporphyria (EPP) Treatment Players by Revenue
3.1.1 Global Top Erythropoietic Protoporphyria (EPP) Treatment Players by Revenue (2016-2021)
3.1.2 Global Erythropoietic Protoporphyria (EPP) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Erythropoietic Protoporphyria (EPP) Treatment Revenue
3.4 Global Erythropoietic Protoporphyria (EPP) Treatment Market Concentration Ratio
3.4.1 Global Erythropoietic Protoporphyria (EPP) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Erythropoietic Protoporphyria (EPP) Treatment Revenue in 2020
3.5 Erythropoietic Protoporphyria (EPP) Treatment Key Players Head office and Area Served
3.6 Key Players Erythropoietic Protoporphyria (EPP) Treatment Product Solution and Service
3.7 Date of Enter into Erythropoietic Protoporphyria (EPP) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Erythropoietic Protoporphyria (EPP) Treatment Breakdown Data by Type
4.1 Global Erythropoietic Protoporphyria (EPP) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Erythropoietic Protoporphyria (EPP) Treatment Forecasted Market Size by Type (2022-2027)

5 Erythropoietic Protoporphyria (EPP) Treatment Breakdown Data by Application
5.1 Global Erythropoietic Protoporphyria (EPP) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Erythropoietic Protoporphyria (EPP) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size (2016-2027)
6.2 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type
6.2.1 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021)
6.2.2 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027)
6.2.3 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2027)
6.3 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application
6.3.1 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021)
6.3.2 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027)
6.3.3 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2027)
6.4 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country
6.4.1 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021)
6.4.2 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size (2016-2027)
7.2 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type
7.2.1 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2027)
7.3 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application
7.3.1 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2027)
7.4 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country
7.4.1 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type
8.2.1 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application
8.3.1 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Region
8.4.1 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size (2016-2027)
9.2 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type
9.2.1 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2027)
9.3 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application
9.3.1 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2027)
9.4 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country
9.4.1 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type
10.2.1 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application
10.3.1 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country
10.4.1 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Clinuvel Pharmaceuticals ALS
11.1.1 Clinuvel Pharmaceuticals ALS Company Details
11.1.2 Clinuvel Pharmaceuticals ALS Business Overview
11.1.3 Clinuvel Pharmaceuticals ALS Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.1.4 Clinuvel Pharmaceuticals ALS Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.1.5 Clinuvel Pharmaceuticals ALS Recent Development
11.2 L'Oréal S.A.
11.2.1 L'Oréal S.A. Company Details
11.2.2 L'Oréal S.A. Business Overview
11.2.3 L'Oréal S.A. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.2.4 L'Oréal S.A. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.2.5 L'Oréal S.A. Recent Development
11.3 Tishcon Corp.
11.3.1 Tishcon Corp. Company Details
11.3.2 Tishcon Corp. Business Overview
11.3.3 Tishcon Corp. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.3.4 Tishcon Corp. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.3.5 Tishcon Corp. Recent Development
11.4 In-Life Co.
11.4.1 In-Life Co. Company Details
11.4.2 In-Life Co. Business Overview
11.4.3 In-Life Co. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.4.4 In-Life Co. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.4.5 In-Life Co. Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Details
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.5.4 Pfizer Inc. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.5.5 Pfizer Inc. Recent Development
11.6 Fenton Pharmaceuticals Ltd.
11.6.1 Fenton Pharmaceuticals Ltd. Company Details
11.6.2 Fenton Pharmaceuticals Ltd. Business Overview
11.6.3 Fenton Pharmaceuticals Ltd. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.6.4 Fenton Pharmaceuticals Ltd. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.6.5 Fenton Pharmaceuticals Ltd. Recent Development
11.7 Teva Pharmaceuticals
11.7.1 Teva Pharmaceuticals Company Details
11.7.2 Teva Pharmaceuticals Business Overview
11.7.3 Teva Pharmaceuticals Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.7.4 Teva Pharmaceuticals Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.7.5 Teva Pharmaceuticals Recent Development
11.8 Mylan N.V.
11.8.1 Mylan N.V. Company Details
11.8.2 Mylan N.V. Business Overview
11.8.3 Mylan N.V. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.8.4 Mylan N.V. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.8.5 Mylan N.V. Recent Development
11.9 Johnson and Johnson
11.9.1 Johnson and Johnson Company Details
11.9.2 Johnson and Johnson Business Overview
11.9.3 Johnson and Johnson Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.9.4 Johnson and Johnson Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.9.5 Johnson and Johnson Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
  • FORMAT: PDF
  • PUBLISHED DATE: Apr, 2021
  • NO OF PAGES: 103